On behalf of the Myocarditis Foundation, we want to extend our deepest gratitude to everyone who joined us for our 20th Anniversary Celebration. Your presence meant so much to us,…
We’re excited to share that Kiniksa’s Pharmaceuticals Phase 2/3 clinical trial of KPL-387, a potential treatment for recurrent pericarditis, is now actively recruiting participants. If you or someone you know…
Dr. Javid Moslehi, M.D., is one of the members of the Myocarditis Foundation’s Medical Advisory Board. Dr. Moslehi and his team have reasoned that using a novel class of therapies…
On Friday May 30th, 2025 the Myocarditis Foundation had the pleasure of attending the “Inflammatory Cardiac & Cardiovascular Disease Symposium”, at NYP Hospital, that was Chaired by Dr. Dor Lotan,…
The Myocarditis Foundation is proud to announce that we have added another pediatric cardiologist to our Board of Directors. Dr. Deipanjan Nandi, comes highly recommended to the Myocarditis Foundation, with…
New Study Confirms: Most Patients with Uncomplicated Myocarditis Face Low In-Hospital Risk Co-Authored by Foundation Co-Founder Dr. Leslie Cooper and Medical Advisory Board Member Dr. Enrico Ammirati The Myocarditis Foundation…
At the recent Heart Failure 2025 conference hosted by the European Society of Cardiology in Belgrade, Dr. Bettina Heidecker, MD, FESC, the Myocarditis Foundation Director of Research and, Head of…
There are many things happening in the world of myocarditis and pericarditis, and all of them are looking very positive for patients. Cardiol Therapeutics has been working on Clinical Trials…
Myocarditis Survivors Face High Risk of Depression, New Study Finds For many survivors of myocarditis, the journey doesn’t end when their heart starts to heal. A new study—funded in part…
Looking for a new way to support the Myocarditis Foundation? Now, your old vehicle—whether it runs or not—can help us save lives. We’re excited to announce a brand-new partnership with…
